23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
22:13 , Jul 11, 2019 |  BC Innovations  |  Distillery Therapeutics

SMPDL3b inhibition or C1P supplementation for diabetic kidney disease

DISEASE CATEGORY: Renal INDICATION: Diabetic nephropathy Inhibition of SMPDL3b or supplementation with the bioactive sphingolipid ceramide-1-phosphate (C1P) could help prevent diabetic kidney disease. In human podocytes, which are injured in diabetic kidney disease, SMPDL3b knockdown...
00:09 , Jun 25, 2019 |  BC Extra  |  Company News

Otezla divestiture makes next launches mission critical for BMS

The molecule that started Celgene's market decline, leading to its eventual takeout, is now being off-loaded to allow BMS to close the deal. Losing it from the line-up will raise the pressure for successful launches...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
19:56 , Apr 10, 2019 |  BC Extra  |  Financial News

Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

At least four biotechs announced venture rounds this week, including rare mineralization disorders play Inozyme and three companies backed by Asian investors. Inozyme Pharma Inc. (Boston, Mass.) raised $67 million in a series A2 round...
19:34 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting production of PD-L1-loaded exosomes for prostate, colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer; colorectal cancer Mouse studies suggest inhibiting RAB27A or SMPD3 alone or in combination with anti-PD-L1 antibodies could help treat prostate and colorectal cancers. In a mouse model of prostate...
22:35 , Apr 8, 2019 |  BC Extra  |  Preclinical News

Tumors release PD-L1 exosomes to evade antitumor immunity

UCSF researchers have found a clue to anti-PD-L1 resistance in exosomes released by tumors, and suggested blocking exosome release as a solution. In a Cell paper published Thursday, the University of California San Francisco team...
21:43 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other...
22:42 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome In vitro studies identified tetrahydrophthalazinone-based inhibitors of T. brucei PDEB1 that could help treat African trypanosomiasis. Chemical synthesis and in vitro activity and cell division assays of tetrahydrophthalazinone analogs yielded two compounds that...
18:56 , Jan 26, 2018 |  BioCentury  |  Emerging Company Profile

Quenching calcium

Inozyme Pharma Inc. is developing an enzyme replacement therapy that could be useful for a broad range of calcification disorders, and provide better efficacy and safety than off-label options. Its sole asset, INZ-701, is a...